Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.

  title={Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.},
  author={Patrick Jault and Thomas Leclerc and Serge Jennes and Jean-Paul Pirnay and Yok-Ai Que and Gr{\'e}gory Resch and Anne-Françoise Rousseau and François Ravat and Herv{\'e} Carsin and R Le floch and Jean Vivien Schaal and Charles Pierre Soler and Cindy Fèvre and Isabelle Arnaud and Laurent Bretaudeau and J{\'e}r{\^o}me Gabard},
  journal={The Lancet. Infectious diseases},
  volume={19 1},

Safety and Tolerability of Bacteriophage Therapy in Severe Staphylococcus aureus Infection

Adjunctive bacteriophage therapy appears to be safe and well-tolerated in critically ill patients with severe S. aureus infection and two weeks of twice daily intravenous administration may be a suitable protocol.

Bacteriophages Improve Outcome in Experimental Staphylococcus Aureus Ventilator Associated Pneumonia.

Phage therapy was as effective as teicoplanin in improving survival and decreasing bacterial load within the lungs of rats infected with methicillin-resistant S. aureus.

The role of phage therapy in burn wound infection management: advantages and pitfalls.

The revival of phage therapy, either in single mode or in combination with conventional antibiotics, may represent a valuable alternative, to treat specific bacterial infections such as burn wound infections, including those caused by multidrug resistant organisms.

Bacteriophages, a New Therapeutic Solution for Inhibiting Multidrug-Resistant Bacteria Causing Wound Infection: Lesson from Animal Models and Clinical Trials

Abstract Wound infection kills a large number of patients worldwide each year. Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa are the most important

Conventional Treatment of Burn Wound Infections versus Phage Therapy

Clinical trials are needed to convince the health care system in those countries that do not have confidence in phage therapy in infectious diseases that it should be implemented in their patient management.

Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics

In vitro populations of a Pseudomonas aeruginosa strain isolated from a burn patient were treated with a single phage, a mixture of two phages, and the combination of phages and antibiotics (at sub-minimum inhibitory concentration (MIC) and MIC levels), and the results show that the two-phages-one-antibiotic combination had the highest killing efficiency against the P. aerug inosa strain.

The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review

It is strongly suggested that the use of purified phage to treat superficial bacterial infections can be highly effective and, by various routes of administration, is safe and without adverse effects.

Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials

A review of the animal models, the various clinical case treatments, and clinical trials for S. aureus phage therapy shows particular promise for bacteriophage treatment, a non-antibiotic strategy to treat bacterial infections, showing particular promise.

A Review of Topical Phage Therapy for Chronically Infected Wounds and Preparations for a Randomized Adaptive Clinical Trial Evaluating Topical Phage Therapy in Chronically Infected Diabetic Foot Ulcers

This work will initially provide results from a systematic literature review of topical phage therapy used clinically in refractorily infected chronic wounds and a synopsis of the preparations for a forthcoming phase II a randomized placebo-controlled clinical trial assessing the therapeutic efficacy exploiting adjunctive personalized phage administration.

Novel Therapeutics for the Treatment of Burn Infection.

Novel therapeutics for the treatment of burn infection employ manipulation of structure and function in host immune cells and pathogen virulence for improved outcomes in burn infection.



Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report

Because of the risk of colistin nephrotoxicity and the family’s will to avoid intensive therapy interventions such as hemofiltration, bacteriophage therapy was initiated under the umbrella of Article 37 (Unproven Interventions in Clinical Practice) of the Declaration of Helsinki.

Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection

The method used to produce a personalized bacteriophage-based therapeutic treatment for a 68-year-old diabetic patient with necrotizing pancreatitis complicated by an MDR A. baumannii infection suggests that the methods described here for the production of bacteriophile therapeutics could be applied to similar cases and that more concerted efforts to investigate the use of therapeutic bacteriaphages for MDR bacterial infections are warranted.

Antibiotics and the burn patient.

Infection in Burns.

Strict infection control measures, constant wound surveillance with regular sampling of tissues for quantitative culture, and early excision and wound closure remain the principal adjuncts to control of invasive infections in burn patients.

Antiseptics for burns.

There is moderate certainty evidence that, on average, burns treated with honey are probably more likely to heal over time compared with topical antibiotics, and there is no clear difference in the hazard of healing (chance of healing over time), between silver-based antiseptics and SSD.

The Potential of Phage Therapy in Sepsis

Recent advancements in immunobiology of bacterial viruses indicate that in addition to their well-known antibacterial action phages have potent immunomodulating properties, which strongly suggest that clinical trials on the efficacy of phages in sepsis are urgently needed.

Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.

This review presents novel strategies for phage-related therapies and describes the current knowledge of natural bacteriophages within the human microbiome to provide an overview of the high number of different methodological concepts.

Phage therapy in clinical practice: treatment of human infections.

This review aims to provide an overview of the potential of phage therapy as a means of treating or preventing human diseases and to explore the phage Therapy state of the art as currently practiced by physicians in various pockets ofphage therapy activity around the world.

Bacteriophage Therapy

The history of bacteriophage discovery and the early clinical studies with phages are described and the recent literature emphasizing research conducted in Poland and the former Soviet Union is reviewed.

Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages

The gene expression profile of peripheral blood monocytes from six donors for twelve immunity-related genes was assessed and the observed immune response was shown to be endotoxin-independent and predominantly anti-inflammatory.